2 results
Approved WMOCompleted
Primary: Safety run-in part (part 1):* to confirm tthe recommended Phase 3 dose regimen (RP3R) of canakinumab in combination with docetaxel. Double-blind, randomized, placebo-controlled part (part 2):* to compare the overall survival (OS) between…
Approved WMOCompleted
The primary objectives of this study are to assess if SAR408701 has a better progression free survival and general overall survival compared to docetaxel, and main secondary endpoints are objective response rate, time to deterioration on health…